Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net income	$ 6,837,000	$ 4,795,000
Adjustments to reconcile net income to net cash (used in) provided by operating activities
Depreciation	3,035,000	1,454,000
Amortization of intangible assets	5,340,000	2,100,000
Stock-based compensation	8,891,000	3,818,000
Non-cash lease expense	1,795,000	455,000
Deferred income tax benefit	(17,540,000)	0
Change in fair value of contingent consideration	1,086,000	(1,528,000)
Change in fair value of warrant liability	121,000	(4,467,000)
Change in fair value of investments	0	(1,110,000)
Gain on acquisition of Sexton Biotechnologies, Inc.	(6,451,000)	0
Stock issued for services	0	30,000
Loss on disposal of assets held for rent, net	333,000	0
Other	504,000	9,000
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net	(7,140,000)	(820,000)
Inventories	(1,237,000)	(65,000)
Prepaid expenses and other current assets	1,769,000	68,000
Accounts payable	1,368,000	(604,000)
Accrued expenses and other current liabilities	(2,530,000)	689,000
Other	0	(436,000)
Net cash (used in) provided by operating activities	(3,819,000)	4,388,000
Cash flows from investing activities
Cash acquired in acquisition of Global Cooling, Inc. and Sexton Biotechnologies, Inc.	1,559,000
Payments related to the acquisition of SciSafe, net of cash acquired		(500,000)
Purchases of property and equipment	(6,819,000)	(370,000)
Purchases of assets held for lease	(5,412,000)	(1,791,000)
Proceeds from sale of equipment	22,000	3,000
Net cash used in investing activities	(10,650,000)	(2,658,000)
Cash flows from financing activities
Payments of contingent consideration	0	(483,000)
Proceeds from sale of common stock, net of $6.2 million of costs in 2020	0	100,251,000
Fees paid related to issuance of common stock	(145,000)	(6,200,000)
Proceeds from line of credit	26,450,000	0
Payments on line of credit	(28,657,000)	0
Proceeds from exercise of common stock options	1,017,000	1,028,000
Proceeds from exercise of warrants	0	40,000
Other	(280,000)	(30,000)
Net cash (used in) provided by financing activities	(673,000)	100,806,000
Net (decrease) increase in cash, cash equivalents, and restricted cash	(15,142,000)	102,536,000
Cash, cash equivalents, and restricted cash – beginning of period	90,456,000	6,448,000
Effects of currency translation on cash, cash equivalents, and restricted cash	(163,000)	0
Cash, cash equivalents, and restricted cash – end of period	75,151,000	108,984,000
Non-cash investing and financing activities
Cashless exercise of warrants reclassified from warrant liability to common stock	2,901,000	33,111,000
Value of issued shares	264,718,000	0
Equipment acquired under operating leases	6,971,000	0
Equipment acquired under finance leases	440,000	0
Purchase of property and equipment not yet paid	305,000	29,000
Reclassification of warrant liabilities to equity upon exercise	0	110,000
Financing costs paid in a prior period	0	130,000
Stock issued as a prepayment of services	0	30,000
Purchase of equipment with debt	0	270,000
Bonus Consideration [Member]
Non-cash investing and financing activities
Stock issued as a prepayment of services	0	314,000
Paycheck Protection Program CARES Act [Member]
Cash flows from financing activities
Proceeds from Loan	0	2,175,000
Payoff of PPP Loan	0	(2,175,000)
Equipment Loans [Member]
Cash flows from financing activities
Proceeds from Loan	1,640,000	0
Financed Insurance Premium [Member]
Cash flows from financing activities
Payments on financed insurance premium	$ (698,000)	$ 0